Pharma Focus Asia
KP - Sustainable Packaging Solutions

Novo Nordisk Plans US$65m Expansion at Its 264-Acre Campus in Clayton


Novo Nordisk is planning to expand its manufacturing operations with US$65 million at its 264-acre campus in Clayton, North Carolina.


The company will initiate  the expansion by the end of 2018 and the expansion will add more than two dozen new positions including operational side.  

The 18-job expansion project is for Novo Nordisk’s growing Diabetes Finished Products (DFP) facility, responsible for the formulation, filling, inspection, assembly and packaging of diabetes and obesity medicines.

The construction is expected to be completed by the fourth quarter of 2019, with full operations starting in 2020.

Clayton facility will add 300 employees in 2018, mostly, manufacturing associates and technicians for the API expansion, as well as positions in IT, automation, metrology and others.

On the other hand, the company’s API operations will formulate ingredients for Novo Nordisk’s portfolio of diabetes medicines, including insulin’s and liraglutide.

Formulation of semaglutide may be a consideration for this site in the future.


NameNovo Nordisk
Parties InvolvedNovo Nordisk
BudgetUS$65 million
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024Equinix accelerated medical research...CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?